RT Journal Article
SR Electronic
T1 Differences in bioprosthetic valve failure after aortic valve replacement in patients with immune mediated inflammatory diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.31.24311322
DO 10.1101/2024.07.31.24311322
A1 Sefton, Christopher
A1 Leaphart, Davis
A1 Klein, Benjamin
A1 Santini, Garrett
A1 Patel, Aditi
A1 Husni, M. Elaine
A1 Vargo, Patrick R.
A1 Roselli, Eric E.
A1 Svensson, Lars
A1 Krishnaswamy, Amar
A1 Kapadia, Samir
A1 Menon, Venu
A1 Khot, Umesh
A1 Wassif, Heba
YR 2024
UL http://medrxiv.org/content/early/2024/08/02/2024.07.31.24311322.abstract
AB Introduction Immune-mediated inflammatory disease (IMID) is a subset of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, and psoriasis that is emerging as a risk factor for many cardiovascular diseases including valvular disease.Objectives To determine whether IMID is associated with frequent and early development of bioprosthetic valve failure (BVF) after surgical aortic valve replacement (SAVR) and transcatheter valve replacement (TAVR).Methods Serial echocardiograms for patients who underwent SAVR and TAVR at Cleveland Clinic between 2000 and 2022 were assessed for time to development of BVF after procedure. ICD10 codes were used to stratify to those with and without IMID. Kaplan-Meier curve and cox proportional hazard regression analysis were used to assess for differences in development of BVF after TAVR and SAVR.Results 351 TAVR patients (52 IMID and 299 controls) and 1961 SAVR patients (300 IMID and 1661 controls) were included. BVF after TAVR occurred in 12 (23.1%) IMID and 21 (7.0%) control patients, respectively, yielding an adjusted hazard ratio of 4.02 (1.81 - 8.92). Time to 50% of patients developing BVF was earlier among IMID, occurring at 6.6 years IMID and not reached in controls (p < 0.001). There were no significant differences in prevalence and time to development of BVF in IMID vs controls after SAVR.Conclusion After TAVR, BVF occurred earlier and more frequently in patients with IMID than controls. This risk should be included during shared decision making among IMID patients considered for TAVR, and may warrant more frequent monitoring post procedure. These differences in BVF were not seen after SAVR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding for reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by Cleveland Clinic IRB Study Number 23-095I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesInternal Cleveland Clinic DatasetIMIDimmune mediated inflammatory diseaseSLEsystemic lupus erythematosusRARheumatoid arthritisCADCoronary artery diseaseSAVRsurgical aortic valve replacementTAVRTranscatheter aortic valve replacementBVFbioprosthetic valve failureAVRAortic valve replacementMCTDmixed connective tissue diseaseDMARDdisease modifying antirheumatic drug